Document Detail


Anti-angiogenic drugs: from bench to clinical trials.
MedLine Citation:
PMID:  16652370     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiogenesis, the generation of new capillaries through a process of pre-existing microvessel sprouting, is under stringent control and normally occurs only during embryonic and post-embryonic development, reproductive cycle, and wound repair. However, in many pathological conditions (solid tumor progression, metastasis, diabetic retinopathy, hemangioma, arthritis, psoriasis and atherosclerosis among others), the disease appears to be associated with persistent upregulated angiogenesis. The development of specific anti-angiogenic agents arises as an attractive therapeutic approach for the treatment of cancer and other angiogenesis-dependent diseases. The formation of new blood vessels is a complex multi-step process. Endothelial cells resting in the parent vessels are activated by an angiogenic signal and stimulated to synthesize and release degradative enzymes allowing endothelial cells to migrate, proliferate and finally differentiate to give rise to capillary tubules. Any of these steps may be a potential target for pharmacological intervention. In spite of the disappointing results obtained initially in clinical trials with anti-angiogenic drugs, recent reports with positive results in phases II and III trials encourage expectations in their therapeutic potential. This review discusses the current approaches for the discovery of new compounds that inhibit angiogenesis, with emphasis on the clinical developmental status of anti-angiogenic drugs.
Authors:
Ana R Quesada; Ramón Muñoz-Chápuli; Miguel A Medina
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Medicinal research reviews     Volume:  26     ISSN:  0198-6325     ISO Abbreviation:  Med Res Rev     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-08     Completed Date:  2006-11-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8103150     Medline TA:  Med Res Rev     Country:  United States    
Other Details:
Languages:  eng     Pagination:  483-530     Citation Subset:  IM    
Copyright Information:
Copyright 2006 Wiley Periodicals, Inc.
Affiliation:
Department of Molecular Biology and Biochemistry, Faculty of Science, University of Málaga, 29071 Málaga, Spain. quesada@uma.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacology*
Animals
Clinical Trials as Topic
Humans
Macular Degeneration / drug therapy*
Models, Biological
Models, Chemical
Models, Molecular
Neoplasms / drug therapy*,  prevention & control,  therapy*
Neovascularization, Pathologic
Signal Transduction
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Model averaging in linkage analysis.
Next Document:  Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.